SPID ®-Technology utilizes compartmentalization to enable sequential release of carbidopa and levodopa, offering a potential new approach for drug delivery in Parkinson’s disease treatment. "Levodopa ...

Dopa-decarboxylase inhibitor + dopamine precursor. ≥18yrs: Do not crush or chew. Patients not receiving levodopa: initially one Sinemet CR 50–200 tab twice daily, at intervals of at least 6 hrs.

Designed for advanced Parkinson’s with poorly controlled motor fluctuations, the infusion delivers steadier levodopa exposure than pills via continuous subcutaneous dosing.

The FDA approved an oral extended-release formulation of levodopa and carbidopa known as IPX203 (Crexont) to treat Parkinson's disease, Amneal Pharmaceuticals announced Wednesday. The treatment is a ...

Treatment with Crexont statistically significantly improved “On” time without troublesome dyskinesia compared with carbidopa/levodopa IR. The Food and Drug Administration (FDA) has approved Crexont ® ...

Rytary is also used to treat PD in adults. To learn more about Rytary’s uses, see “Is Rytary used for Parkinson’s disease?” and “Is Rytary used for other conditions?” below. Rytary comes as a capsule ...

HONG KONG — A new technology promises to deliver levodopa at more constant levels over time. It depends on a folded, accordion-like structure inside a gelatin capsule. When swallowed, the capsule ...

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.S. Food and Drug Administration approved INBRIJA™ for intermittent treatment of OFF episodes in ...

A once-a-week Parkinson’s injection could replace multiple daily pills, thanks to a new slow-release formulation developed by researchers. It promises easier treatment, fewer missed doses, and better ...

Amneal to hold CREXONT launch symposium and scientific presentations at the International Congress of Parkinson’s Disease and Movement Disorders on Sept. 27 – Oct. 1, 2024 BRIDGEWATER, N.J.--(BUSINESS ...